Investigator-Sponsored Studies (ISS) Program
The Investigator-Sponsored Studies (ISS) Program supports independent researchers conducting clinical and observational studies to address evidence gaps in Novo Nordisk therapeutic areas and improve patient outcomes.
Funder: Novo Nordisk
Due Dates: July 15, 2026 (Special window) | October 1, 2026 (Regular) | March 1, 2027 (Regular)
Funding Amounts: Study drug, funding, or both; institutional overhead capped at 25% when funding is requested
Summary: Supports independent studies that build evidence about Novo Nordisk products and therapeutic areas to improve patient outcomes.
Key Information: Clinical studies must use study drug provided by Novo Nordisk, Inc.
Description
Novo Nordisk, Inc. (NNI) runs the Investigator-Sponsored Studies Program to support independent research addressing evidence gaps, unmet needs, and potential areas of innovation. Its principal areas of interest are diabetes, liver health, obesity, cardiovascular disease, and rare diseases. Ideas outside the listed areas are welcome, though protocols aligned with stated interests are more likely to receive support.
The program supports clinical studies—interventional drug research using data from humans or human specimens—and observational studies that examine standard care without changing or intervening in it. Observational research may use sources such as claims data, medical charts, electronic healthcare records, or meta-analyses.
